FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

Semax

ACTH 4-10 analog / Heptapeptide Semax

Cognitive & Neuro

Semax is a synthetic heptapeptide analog of the ACTH(4-10) fragment, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a neuroprotective and nootropic agent. It is approved in Russia and Ukraine for the treatment of stroke, transient ischemic attacks, cognitive disorders, optic nerve atrophy, and peptic ulcers. Semax enhances BDNF expression, modulates serotonergic and dopaminergic neurotransmission, and provides neuroprotection without any hormonal (adrenocorticotropic) activity despite its ACTH-derived structure.

작용 메커니즘

Synthetic analog of ACTH 4-10 fragment with a Pro-Gly-Pro C-terminal extension. Increases BDNF and NGF expression in the hippocampus. Enhances attention, memory, and learning without hormonal effects of full-length ACTH. Neuroprotective against oxidative stress.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Research protocols use 200-600mcg intranasally 2-3 times daily. Russian approved protocols use 0.1% or 1% nasal drops. Higher concentrations (1%) used for acute neuroprotection. Typical cycles are 2-4 weeks.

연구 노트

Clinical Research Status

Semax has been approved in Russia since 2001 as a nasal spray (0.1% and 1% solutions) for acute ischemic stroke, cognitive impairment, and optic nerve diseases. Large-scale Russian clinical trials involving stroke patients demonstrated reduced neurological deficit scores and improved functional outcomes when administered within 6 hours of ischemic events. It has not entered FDA regulatory pathways and remains unapproved in Western markets. The 1% formulation (N-Acetyl Semax Amidate, or NASA) is used in more severe neurological conditions while the 0.1% is used for cognitive enhancement.

Key Published Findings

A 2005 study in Doklady Biological Sciences showed Semax increased BDNF mRNA expression in the rat hippocampus and basal forebrain by 1.4-3x baseline within 24 hours. Clinical stroke trials published in Zhurnal Nevrologii i Psikhiatrii demonstrated 2.4x faster neurological recovery versus controls when administered acutely. Semax was shown to differentially regulate 24 genes in glial cells related to neuroinflammation and neuroprotection in a 2013 transcriptomics study. Research confirms no adrenocorticotropic effects despite the ACTH backbone, as the melanocortin-receptor binding motif was deliberately excluded from the fragment.

Safety Profile

Extensive clinical use in Russia over 20+ years has revealed no significant adverse effects, hormonal disruption, or organ toxicity. Semax produces no sedation, tolerance, withdrawal, or dependence, and no drug-related deaths have been reported. The peptide is rapidly degraded by aminopeptidases with a plasma half-life of approximately 2 minutes, though CNS effects persist for 20-24 hours due to intracellular signaling cascades. Nasal administration avoids first-pass metabolism and achieves CNS penetration without systemic accumulation.

Drug Interactions & Contraindications

No formally documented drug interactions exist in published literature, though the serotonergic modulation suggests theoretical caution with SSRIs or MAOIs at high doses. Contraindicated in patients with acute psychosis or severe manic episodes due to its stimulating cognitive effects. May theoretically potentiate the effects of stimulant medications (amphetamines, methylphenidate) through dopaminergic enhancement. Not recommended in pregnancy due to insufficient safety data despite the absence of hormonal activity.

Comparison to Related Compounds

Semax is more stimulating and neuroprotective compared to Selank, which is primarily anxiolytic; Russian clinicians frequently prescribe them together for complementary effects. Unlike racetam nootropics, Semax has a well-defined mechanism (BDNF upregulation, TrkB signaling) and documented neuroprotective efficacy in stroke. Compared to cerebrolysin (another Russian-approved neuroprotective), Semax offers non-invasive nasal administration versus required IV infusion. The N-Acetyl Semax Amidate (NASA) analog offers approximately 60x greater stability and potency versus unmodified Semax.

Community Observations

Users report enhanced verbal fluency, motivation, and mental clarity typically within 10-30 minutes of intranasal administration, lasting 4-8 hours. The 0.1% solution (50 mcg/drop) is most commonly used at 2-3 drops per nostril, 2-3 times daily for cognitive enhancement. Some users report a mild stimulant-like quality that can interfere with sleep if dosed too late in the day. Combining Semax with Selank is considered the gold-standard peptide nootropic stack in the biohacking community, providing focused cognition without anxiety.

반감기

~2-3 minutes (intranasal effects last 4-6 hours)

재조성

Bacteriostatic water (BAC) for SubQ; saline for nasal

보관

건조한 상태

Refrigerate 2-8C up to 12 months.

재조성된 상태

Refrigerate 2-8C. Use within 14 days.

미국 법적 상태

Research chemical (approved in Russia)

또는 알려진 이름으로

ACTH 4-10 analogHeptapeptide Semax

자주 묻는 질문

Semax란 무엇인가요?

Semax is a synthetic heptapeptide analog of the ACTH(4-10) fragment, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a neuroprotective and nootropic agent. It is approved in Russia and Ukraine for the treatment of stroke, transient ischemic attacks, cognitive disorders, optic nerve atrophy, and peptic ulcers. Semax enhances BDNF expression, modulates serotonergic and dopaminergic neurotransmission, and provides neuroprotection without any hormonal (adrenocorticotropic) activity despite its ACTH-derived structure.

Semax는 어떻게 작용하나요?

Synthetic analog of ACTH 4-10 fragment with a Pro-Gly-Pro C-terminal extension. Increases BDNF and NGF expression in the hippocampus. Enhances attention, memory, and learning without hormonal effects of full-length ACTH. Neuroprotective against oxidative stress.

Semax의 미국 규제 현황은 어떤가요?

Research chemical (approved in Russia)

Semax의 반감기는 얼마인가요?

~2-3 minutes (intranasal effects last 4-6 hours)

Semax의 다른 이름은 무엇인가요?

ACTH 4-10 analog, Heptapeptide Semax

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기